Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I6XA
|
||||
| Former ID |
DNC004384
|
||||
| Drug Name |
(2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol
|
||||
| Synonyms |
3-(6-Amino-purin-9-yl)-nonan-2-ol
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
CCCCCCC(C(C)O)N1C=NC2=C1N=CN=C2N
|
||||
| InChI |
1S/C14H23N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17)/t10-,11+/m1/s1
|
||||
| InChIKey |
IOSAAWHGJUZBOG-MNOVXSKESA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A3 receptor | Target Info | Inhibitor | [2] | |
| CGMP-dependent3',5'-cyclic phosphodiesterase | Target Info | Inhibitor | [1] | ||
| Adenosine A2a receptor | Target Info | Inhibitor | [2] | ||
| KEGG Pathway | Purine metabolism | ||||
| cGMP-PKG signaling pathway | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholism | |||||
| NetPath Pathway | TSH Signaling Pathway | ||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling eventsR-HSA-418457:cGMP effects | |||||
| G alpha (s) signalling eventsR-HSA-187024:NGF-independant TRKA activation | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| Monoamine Transport | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | J Med Chem. 2005 May 19;48(10):3449-62.The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. | ||||
| REF 2 | J Med Chem. 1995 May 12;38(10):1720-35.Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.